

# Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy

Luigi DI BELLA & Giuseppe DI BELLA

Di Bella Foundation, Bologna, Italy

*Correspondence to:* Dr. Giuseppe Di Bella, MD.  
Di Bella Foundation  
Via Marconi 51, Post Code 40122 Bologna, Italy.  
TEL: +39 051 239662; FAX: +39 051 230369; E-MAIL: [posta@giuseppedibella.it](mailto:posta@giuseppedibella.it)

*Submitted:* 2015-10-02 *Accepted:* 2015-11-15 *Published online:* 2015-00-00

*Key words:* **Di Bella Method (DBM); retinoid;  $\beta$ -carotene; betacarotene; retinoic acid (ATRA); vitamin A; vitamin D; vitamin E; melatonin**

Neuroendocrinol Lett 2015; **36**(7):101–116 PMID: ----- NEL360715AXX ©2015 Neuroendocrinology Letters • [www.nel.edu](http://www.nel.edu)

## Abstract

**OBJECTIVE:** The aim of the liposoluble vitamin solution in the DBM formulation is to enhance the bioavailability, the stability, the half-life and the therapeutic efficacy of the components without resorting to excessive or toxic doses.

**METHOD:** The DBM vitamin solution contains 0.5 grams of vitamin A palmitate ester, 0.5 grams of all-trans-retinoic acid (ATRA), and 2 grams of  $\beta$ -Carotene, in 1 000 grams of vitamin E acetate ester which stabilizes the other components, protecting them from oxidation. The solution is administered before meals at the dose of 90 to 150 mg per kg of body weight. The quantities have a determining value for a pharmacological result. No phenomena of overdose and/or toxicity have ever been detected in the tens of thousands of people who have used the solution with this formulation and dosage.

**RESULTS:** Thanks to the synergic effect of the components and their antioxidant, free antiradical, cell-membrane stabilizing, differentiating and cytostatic properties, this solution has constantly produced positive therapeutic responses. Favourable effects have been observed in the prevention and treatment of neoplastic diseases, as well as on immunity, physiological growth, trophism and functionality of tegumental, respiratory, digestive, urogenital and exocrine gland epithelia. A significant antidegenerative effect has also been observed in pretumoral stages. Studies have been published reporting 754 cases of various types of tumor which have greatly benefited from the use of this vitamin solution synergically and factorially reinforced by the other components of the DBM, such as Melatonin, Vitamins D and C, D2 receptor agonists, and GH inhibitors like Somatostatina and analogs.

**CONCLUSIONS:** In view of the documented results achieved, we believed it useful to provide the scientific community with the details of the formulation, preparation, posology, rationale, mechanism of action, biochemical, molecular and physiological bases, indications and clinical findings relating to the DBM liposoluble vitamin solution.

## INTRODUCTION

The components of the DBM liposoluble vitamin solution are vitamin A palmitate ester, Betacarotene and All Trans-Retinoic Acid (ATRA), and the acetate ester of Alphatocopherol, formidable exergons used in quantities of fractions of milligrams.

The quantities have a determining value, providing a pharmacological result and not creating toxicity phenomena. They regulate anti-infection, anti-degenerative, anti-tumoral homeostasis and stabilize cellular membrane potentials.

In addition to protecting the cellular membrane, vitamin E carries out an anti-oxidising defence action. At the prescribed doses, the composition is designed never to reach accumulation or toxicity.

This mixture is important for elimination of free radicals, reducing their toxic effects and alterations to the microcirculation. The inflammatory states produced by free radicals can cause damage to various organs, including the respiratory system, leading in the long run to pulmonary foci, alteration of lung parenchyma, emphysema, altered bacterial response, immunitary complexes and the formation of intravascular clots. The elimination of free radicals together with the epithelioprotective and immunostimulating effect of retinoids solubilized in vitamin E leads to the reperfusion of ischemic organs and the improvement of the trophism functionality of organs and tissues.


## COMPONENTS

palmitate axerophthol	0.5 g
retinoic acid	0.5 g
betacarotene	2 g
D,L-alfa-tocopheryl acetate	1 000 g

## STRUCTURE FORMULAS


### Betacarotene (C<sub>40</sub>H<sub>56</sub>)

$\beta$ - $\beta$ -carotene; *trans*- $\beta$ -carotene; (*all-E*)-1,1'-(3,7,12,16-tetramethyl-1,3,5,7,9,11,13,15,17-octocanonaene-1,18-dyl)bis[2,6,6-trimethylcyclohexene]; E160a.




### Vitamin A

Retinol or Axerophthol (A1) (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)-nona-2,4,6,8-tetraen-1-ol




### Axerophthol or Retinol

(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol




### Retinyl palmitate (C<sub>36</sub>H<sub>60</sub>O<sub>2</sub>)




### Trans-retinoic acid



3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-*all-trans*-tetraenoic acid, (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl) nona-2,4,6,8-tetraenoic acid.




### Vitamin E

$\alpha$ -tocopherol (5, 7, 8 trimethyltolcol)



**$\beta$ -tocopherol** (5, 8-dimethyltolcol) **$\gamma$ -tocopherol** (7, 8-dimethyltolcol)**D,L- $\alpha$ -tocopherol acetate**

3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopiran-6-ol acetate; (2RS, 4'R,8'R)-2,5,7,8-Tetramethyl-2-(4',8',12'-trimethyltridecyl)-6-cromanil acetate.

**TECHNOLOGY**

The raw materials must be of maximum purity and stored at the correct temperature. Once the container has been opened, their storage requires the introduction of inert gases (e.g. nitrogen) and observance of manufacturer and pharmacopeia indications.

Trans retinoic acid and Betacarotene are in solid form, while Vitamin A Palmitate (at room temperature) and alfa Tocopherol acetate are liquid and highly viscose. They can be mixed together to achieve molecular level dispersion. The solution can be prepared by gentle stirring. Stirring must be performed using an efficient temperature controller, to be selected according to the size of the batches to be prepared. The preparation methods differ slightly depending on the apparatus used, although the general principles are similar. Anhydrous acetone and ethyl alcohol can be used as solubilisation coadjuvants of retinoic acid and betacarotene. In this case, it is necessary to ensure that they are completely eliminated under a nitrogen flow.

Nitrogen

In all cases, whether using acetone or alcohol, nitrogen must be used at the end of processing to eliminate these substances. Cylinders of top purity pharmaceutical

nitrogen can be purchased from suppliers of therapeutic oxygen and/or other gaseous substances. The nitrogen contained in these cylinders is pressurised at 200 atmospheres; in order to use the nitrogen, the cylinder must be fitted with a flow reducer equipped with two gauges (to measure the pressure inside the cylinder and the discharge pressure). The discharge pressure can be varied by means of the fine adjustment control on the reducer. The nozzle is connected to a tube which has an in-line porous septum filter. The purpose of the filter is to trap the metal impurities coming from the walls of the cylinder, which could be carried along by the flow of gas: these impurities would be a potent oxidation catalyser and therefore harmful for the stability of the product.

It should be borne in mind that, except for vitamin E acetate, these substances are sensitive to:

1. light
2. air (oxidative alterations)
3. certain temperatures

Light

Particular care must be taken in preventing exposure of the substances to direct sunlight (light with radiation in the ultraviolet spectrum). It is thus necessary to work using opaque receptacles and in red-light rooms.

Air

The components are all sensitive to oxidation by oxygen in the air: the most sensitive component is certainly Beta-carotene, due to the presence of an extensive  $\pi$  system, which also gives it its typical brick red colour. Since tocopherol acts as a radical scavenger, it can capture the oxygen in the air, forming a labile bond with the unpaired electrons of the oxygen molecule and partly protecting Beta-carotene from oxidation: it is however possible to prevent this bond from occurring. This can be done by exploiting the greater solubility of nitrogen in lipids with respect to oxygen, saturating the tocopherol with nitrogen before adding the Beta-carotene and the other retinoids.

Temperature

It should be noted that in the absence of oxidants, the resistance of the substances to thermal degradation is relatively good and in any case depends on the processing time. It is advisable not to exceed a temperature of 40 °C during processing.

Preparation method according to Italian decree dated 16-06-98 no.186, published in the official gazette dated 17-06-98 no.139.

Preparation of 1000 g of retinoid solution con acetone or ethyl alcohol 95 °C as organic solvent. The technician must work under a hood wearing gloves, mask and goggles, at room temperature.

**Step 1:** Weigh 0.5 g of trans-retinoic acid, which must be reduced to VERY FINE powder, and then dissolved in a mortar by adding the organic solvent in DROPS;

still working in the mortar, add 2 gr of Beta- carotene in organic solvent. (N.B. the remaining powder must be stored COLD and under nitrogen).

**Step 2:** The dissolved powders are poured into the mixer and around 100 cc of vitamin E is added slowly while mixing. Gurgel the nitrogen at medium flow rate until the organic solvent has been eliminated.

**Step 3:** Gradually increase the temperature to  $40\pm 2^{\circ}\text{C}$  while continuously stirring. Leave to cool for 15–20 minutes and slowly add another 100 cc of vitamin E, stirring all the time; increase the mixing speed slightly for about 10 minutes.

**Step 4:** Add 0.5 g of axerophthol palmitate in drops and continue to stir for 10 minutes; add another 100 cc of vitamin E, keeping the stirring speed low for at least 15 minutes; repeat this operation up to 1 000 g of vitamin E. Close the mixer lid and leave it to stir for at least 6 hours.

**Step 5:** Pour the mixture into dark glass bottles and close them immediately; store them away from light and heat (if not used immediately, introduce nitrogen flow before sealing the bottles).

#### Materials

- Chemical hood
- Red light.
- Mixer for high viscosity liquids with temperature controller
- 5 mc nitrogen cylinder, 200 bar, with flow system.
- 0.22 micron gas filter (Millipore)
- Stainless steel container
- Dark glass bottles.

#### Analyses

The solution of retinoids in tocopherol must be CRYSTAL-CLEAR, dark red, viscous, odourless, tasteless. The simplest and most direct evaluation criterion is the transparency; true solutions are, in fact, optically empty, nor is there evidence of Tyndall effect as, instead, is normal in solubilised forms. Absence of acetone.

Check of the homogeneity of dispersion of vitamin A, Beta-carotene, retinoic acid in vitamin E (titres). Check for the presence of any alteration compounds formed during preparation.

#### Long-term stability

**Storage:** The finished product should be stored in dark glass bottles at room temperature. For ideal storage, the bottles should be filled using nitrogen insufflation.

**Dosage-labelling:** The mixture should be taken in the morning before eating, at the dose, referring to the vitamin E content (which alone represents  $997 \times 1000$ ), of 90 to 150 mg per Kg of body weight. It is advisable not to eat or drink acid substances (e.g. lemons) at the same time as the mixture so as not to alter its absorption and activity. Do not use a metal spoon in order to

avoid oxidation. The dark glass bottles should be correctly labelled.

**Using titration curves and HPLC analyses, it is necessary to check the stability of the solution, ascertain the presence of any undesired molecules such as cis retinoic acid and make sure the organic solvent has been eliminated.**

## RATIONALE OF THE THERAPY

The solution of retinoids in vitamin E was formulated by Prof. Luigi Di Bella on the basis of biological, biochemical, pharmacological and physiological studies, carried out over the course of many years, with a vast range of clinical indications mainly for the prevention and treatment of tumors, but also in view of their anti-degenerative, anti-infectious and trophic effects. The documented primary role of retinoids, interacting with vitamin E in vital reactions, in the trophism and functionality of organs and tissues, in anti-cancer, immuno-neuro-endocrine and antidegenerative homeostasis, explains the rationality and logic of the vast range of indications for the non-toxic formulation of this solution. To understand the enormous value of retinoids in the setting of biological economy, it is sufficient to consider that they provide the large amounts of energy needed for growth and for the physiological order of growth, contributing to anti-cancer homeostasis. The growth of a living substance requires a considerable amount of energy, but the physiological order of growth requires an equally large amount of energy. Retinoids are the most potent non-hormonal activators of growth, but only of ordered, functional growth for optimum biological equilibrium, while they inhibit the aimless and disorderly neoplastic growth, directing the tumor towards apoptosis. Together with Melatonin, they are the only differential toxicity molecules that have a cytostatic effect on tumor cells but not on healthy cells. Retinoids thus have the ability to preserve and enhance the trophism, vitality and efficiency of healthy cells at the same time as diminishing the progression, vitality and marked mutagenic behaviour of the neoplastic phenotype. A tumour is a deviation from normal life, which means that it is necessary to redirect the deviated reactions to their normal status by reinforcing the means considered physiologically essential for life. Retinoids intervene in two critical aspects of tumoral biology: the uncontrolled proliferation and the sequence of mutations, common denominators of all tumors. The cytostatic properties of retinoids counter the proliferation of the tumor cells, while their differentiating properties counter the progression of mutations with which, during its evolution, the neoplastic phenotype selects and maintains a series of advantages, becoming more and more aggressive, resistant, mobile and toxic. There is now an enormous quantity of literature that confirms the multiple and determining therapeutic properties of axerophthol, retinoic acid and Betacar-



tene (Sommer & Vyas 2012; Alizadeh *et al.* 2014; Brun *et al.* 2013; Álvarez *et al.* 2014; Angulo-Molina *et al.* 2014; Das *et al.* 2014; Israel *et al.* 1980; McLaren & Kraemer 2012; Papadimitrakopoulou *et al.* 2009; Prasad *et al.* 2003; Chen *et al.* 2014; Carratù *et al.* 2012; Alizadeh *et al.* 2014; Israel *et al.* 1980; Ling *et al.* 2012; Mettlin 1984; Nesaretnam 2008; Smith 1998; Zhang *et al.* 2012; Barroga *et al.* 2000; Black 2013; Franke *et al.* 2013).

The basic outlines of the mechanism of action of retinoids in the growth and repair of tissues were already described back in 1985 in volume 113 of the Ciba Foundation Symposia (Ciba Foundation Symposia 1985).

The DBM retinoid solution, together with the other components such as vitamin D<sup>3</sup>, C, and Melatonin, acts on the biological conditions to create an environment that is not pharmacologically toxic but is biochemically unfavourable to the neoplastic biology, having a negative effect on the reactions that take place in the evolution of the tumor, at the same time activating the reactions involved in the healing process. Despite the scientific evidence, in the rare cases in which oncological protocols foresee the use of retinoic acid (the only one of the retinoids that is used, and only in promyelocytic leukemia), for its lability and easy oxidability (common to all retinoids), its efficacy is limited by the absence of the protective and antioxidizing functions of the high doses of Vitamin E and Beta carotene present in the DBM solution. Considering the number of cases treated by Prof Di Bella and by his students and the doctors who prescribe the solution, it can be estimated that since the late 1960s at least 50,000 people have benefitted from taking this solution, without any toxic effects. The literature contains numerous publications concerning a total of 754 cases of various forms of tumors, including retrospective observational studies on NSCLC, lymphoproliferative diseases, cervicofacial tumors, breast cancer, prostate cancer, etc. All these studies document the positive anti-cancer non-toxic effect of this vitamin solution, in tandem with the other components of the DBM, such as Melatonin, prolactin inhibitors, somatostatin, Vitamins D<sup>3</sup> and C (Todisco *et al.* 2001; Todisco 2009; Norsa & Martino 2006; Norsa & Martino 2007; Di Bella L *et al.* 1979; Di Bella 1998; Di Bella 2005; Di Bella & Gualano 2006; Di Bella 2010; Di Bella 2011; Di Bella *et al.* 2012; Di Bella & Colori 2012; Di Bella *et al.* 2013; Di Bella *et al.* 2013; Di Bella *et al.* 2013; Margheri *et al.* 2012).

The term retinoids includes vit. A or Retinol, which chemically speaking is a primary alcohol, the provitamins A (around ten), which include Carotenoids, the byproducts of vit. A, such as Retinoic Acid, the aldehyde known as Retinene, an essential component of the visual purpura of the rods, and retinal photoreceptors, essential for vision, a process that involves a recall of vitamin A from the blood to the retina, studied by Wald (Wald 1960).

Retinoids are associated by a common metabolic destiny, albeit with specific peculiarities and different

levels of activity. They have some structural chemical elements in common, such as the beta ionone and the four unsaturated bonds in the side chain. They differ in their terminal chemical function which binds to the last carbon atom of the side chain. The structure formula of retinoids, which chemically speaking are hydrocarbons, makes it possible to imagine their lability and easy oxidability (Álvarez *et al.* 2014; Das *et al.* 2014; Eroglu & Harrison 2013). Thus, in order to stabilize them, avoid oxidation, enhance their activity, bioavailability and half-life, the retinoids are solubilized in the DBM vitamin solution in high doses of vitamin A which, as well as in turn having a number of documented anticancer mechanisms, maintains its pharmacological and therapeutic properties. At intestinal level, vitamin A is absorbed chemically conjugated with substances that make it more stable, such as palmitic acid; vitamin A is thus present in the DBM solution in the form of palmitic ester (Reboul 2013; Takahashi *et al.* 1997; Vilanova & Solans 2015). The absorption of retinoids is facilitated by lipids and bile acids. Through the lymph ducts, the retinoid esters collect rapidly, especially in the liver which contains up to 90%; from the liver, they are mobilized as required and/or eliminated through the bile acids. The liver has a leading role in the metabolism of vitamin A which, with the retinoids, plays a fundamental role both in preventing and treating tumors, and also tends to limit the consequences caused by the tumor and by the usual anticancer treatments. Concentrations of vitamin A of up to 100–300 mg/kg have been detected in the liver. Vitamin A is transported through the blood by protein complexes associated with a prealbumin fraction and thyroxine. These substances are vital for its transport and diffusion to the cell organelles like mitochondria, the Golgi network and the cell nucleus. The sero-protein, thyroid and hypophysis equilibrium is therefore essential for the transport and use of vitamin A. The blood concentration of vitamin A can increase through food intake or due to tissue lipolysis caused by rapid weight loss, but homeostatic regulation mechanisms tend to maintain a stable concentration in the various cases. A first indication of liver disease is an alteration in the absorption and metabolism of vitamin A and retinoids, as in alcohol abuse disorders, chemotherapy and the use of oral contraceptives. In the various stages of the menstrual cycle, the rate of vitamin A; in the first stages of life it is mainly absorbed through milk where it is present in ester form. The Retinol-Binding-Protein complex is the keystone of the transformation of chemical energy at cell level, through the extremely delicate processes of vision, growth and reproduction.

From a protein point of view, the alcoholic or vitamin A (axerophthol), aldehydic (Retinene), acid (Retinoic acid) and Betacarotene byproduct varieties, with molecularly different mechanisms, influence life in its essential and delicate expressions of cell energy dynamics. It is no longer possible to deny the primary

role of retinoids in preventing and treating carcinogenesis (Hinds *et al.* 1997). A simple and easily recognizable demonstration is the limitation and subsequent suppression of the aggressive behaviour of early-stage melanomas on local application of a few drops of the DBM solution. A melanocytic mole can be gradually normalized in a few months by daily application of the solution. The true possibility of retinoid assimilation depends on the ability of the intestine to extract them; they are transferred, through the circulation and lymphatic system, to the liver where they are deposited and processed, above all in the Kupfer cells, then mobilized to satisfy organic requirements (Reboul 2013).

Small amounts of vitamin A pass through the renal tubule epithelia; the presence of vitamin A is essential even in the first few days after conception for the formation and function of the placenta, and after the first 10–20 days the embryo starts to synthesize the association of proteins with vitamin A and retinoids. Although there may be only a small amount of vitamin A in our bodies, it is deposited in the liver cells, where it is accumulated and protected against attack from the oxidating agents. The integrity of our skin, airways, glandular and urogenital systems, the ability of these tissues to react to trauma and/or infection is always certainly an expression of a sufficient presence of vitamin A, whose sphere of action is therefore immense and vital (Hinds *et al.* 1997). For any kind of damage to these tissues, vitamin A is the supreme remedy. In appropriate quantities it causes no harm; 40–50 000 units per day are tolerated without damage. By regulating the thickness of the skin, trophism and evaporation, retinoids are involved in body temperature control mechanisms. A deficit of retinoids causes thickening and dryness, and reduces heat conduction by evaporation, turning the skin into a heat insulator. A tumor patient undergoing conventional treatments, which lead to a deficiency of vitamin A, can experience an increase in body temperature which is non-febrile hyperthermia. In hyperthermia the regulation mechanisms are altered due to the absence of thermolysis and heat dispersion. The skin becomes thicker due to the increase of the horny layer, it loses elasticity and the sweat and sebaceous glands tend to atrophize, as do the hair bulbs which leads to alopecia. These regressive-degenerative phenomena also extend to the epithelium coating of the respiratory, digestive, genito-urinary and glandular systems. The skeletal system is also affected by a deficiency of Vitamin A. An international consultation group of the WHO studied vitamin A deficiency states in poor countries, and observed symptoms such as follicular hyperkeratosis, skin infections, eczema, bronchitis, cystopyelitis, etc. In areas where the deficiency is severe, there was an increased frequency of fetal malformation, degenerative inflammatory disorders of the generative tract and of mammary secretions. Teratogenic effects and miscarriages were also frequent, while skeletal malformations depend on the altered activity of the osteoclasts that

control the metabolism of calcium. The immunitary system is also impaired by a deficiency of vitamin A, affecting various mechanisms such as the synthesis of immunoglobulins and a leuko-erythro-plateletpoietic depression of the bone marrow (Álvarez *et al.* 2014; Flajollet *et al.* 2013).

Vitamin A probably plays a determining role in cell proliferation, also through metabolism of the polyamines, on the regulation of reproduction and tissue growth speed. The metabolism of some amino acids such as Ornithine and Lysine, of the respective decarboxylases and the interactions with Betacarotene is still being studied. There are three forms of the yellow-orange pigment carotenoids: alpha, beta and gamma. The most common form is Beta-carotene, a terpene provitamin with a slow metabolism producing two molecules of vitamin A (Eroglu & Harrison 2013). Betacarotene consists of 8 isoprene units, cyclised at each end, and is a precursor of vitamin A which is synthesized in the liver thanks to the enzyme carotenase (Goodman *et al.* 1967; Leuenberger 2001). Like all retinoids, Betacarotene is a hydrocarbon and, as such, is a typically apolar molecule, devoid of fillers and inert. It can therefore be included among those molecules, or those apolar parts of molecules, that belong to fatty acids, i.e. to those structures that contribute to form one of the basic elements of life: the cell membrane. It is like a barrier, an obligatory gateway through which everything must pass from the cell outwards and vice versa to allow the cell to live. As a molecule ( $C_{40}H_{56}$ ), Betacarotene has a direct preventive and therapeutic action in neoplastic diseases, as demonstrated by the considerable number of relative publications. It is also involved in the mechanism of bone growth and, in general, contributes to the correct functioning of many organs. It has a strong antioxidant effect, thus protecting cells from the damage caused by free radicals and plays a fundamental role in the immune system (Lo *et al.* 2014; Han *et al.* 2014). Onogi *et al.* (Onogi *et al.* 1998) demonstrated the direct antiproliferative effect on colon cancer cells of the carotenoids, regardless of their conversion to ATRA. It has been shown that carotenoids can exert their tumoral suppression effect even without being converted into their metabolites, retinol or retinoic acid. Beta-carotene 15, 15'-monooxygenase is an enzyme belonging to the class of oxydoreductases, which catalyzes the reaction:  $\beta\text{-carotene} + O_2 \rightleftharpoons 2 \text{ retinale}$ , and requires bile salts and Fe. Unlike retinol, the body takes in the necessary quantity of Beta-carotene, eliminating any excess amounts. Epidemiological studies have shown a significant correlation between the onset of cancer and the intake (in high doses for several years) of betacarotene through food only in heavy smokers, confirming on the other hand the positive anticancer effect of betacarotene in all tumors in non-smokers. The cancerogens involved in smoking, such as nitrosamine, combustion products, hydrocarbons, 3–4 Benzopyrene, together with the oxidant effect of nicotine, in subjects exposed to extraor-

dinary oxidative stress due to the amplified effect of the high concentrations of oxygen in the lungs, degrade the labile and easily oxidable molecule of betacarotene by asymmetric splitting, releasing toxic metabolites (CBP). The degradation of Betacarotene, in addition to inactivating its particular and specific anticancer properties, causes a deficiency of its physiological metabolites, retinoic acid and axerophthol, fundamental molecules in the treatment of tumors for their cytostatic, differentiating, epithelioprotective, immunostimulating and trophic effect. Highly reactive products of the irregular degradation of carotenoids (CBP), including aldehydes and epoxides, form during these oxidative reactions.

The mechanisms of degradation of Betacarotene include the influence of activated neutrophils; the mitochondrial toxicity that the CBPs can cause, with effects on cell respiration, on variations in the potential of the mitochondrial membrane and relative patency and on dislocation of the nucleotide adenine was also evaluated. The inhibition of mitochondrial respiration is accompanied by a reduction in the cytosolic content of sulfureted proteins, of GSH and redox state, and a considerable accumulation of malondialdehyde. It is only recently that several authors have pointed out the need to counter the degradation of Betacarotene by means of potent biological antioxidants such as Vitamin E, thereby neutralizing the strong cancerogenic and toxic effects of the CBPs and the serious deficit of fundamental anticancer molecules (Al-Malki & Moselhy SS 2013); Khuri *et al.* 2001; Liede *et al.* 1998; Lubin *et al.* 2008).

With the solution of retinoids in Vitamin E, prof. Luigi Di Bella anticipated these therapeutic concepts by more than 30 years, identifying the biochemical, molecular and pharmacological bases for an ideal and constant therapeutic response without any toxicity. It is only the contemporary, non-sequential administration of retinoids in vitamin E, in a molecular dispersion (thus in solution, and not in suspension) which represents the correct response (available and used for decades with positive effects and no toxicity) to this problem, stabilizing the three retinoids.

The constant availability of a sufficient quantity of Betacarotene obtained as described above is fundamental for biological equilibrium, homeostasis, preservation and recovery of cell and mitochondrial membrane functionality, receptorial physiology, ion channels, membrane potential, intercellular communication and cell adhesion. The DBM solution forms a reserve of Betacarotene that is always readily available when due to oncological, degenerative or infectious diseases an increase in the requirements Betacarotene or its metabolites – Axerophthol and Retinoic acid – is required. Axerophthol and Retinoic acid are therefore reinforced by Betacarotene in the DBM solution; and to obtain maximum efficacy and effect, the ratio of Betacarotene to Axerophthol (or vit. A) and Retinoic acid must be four to one. The continued administration

for many years of the DBM solution has never caused an accumulation or toxicity, or cases of carotenemia whose presence is instead due to a deficiency of carotenase, hepatic dysfunction or an excessive dietary intake of carotenoids. Carotenemia is characterized by the jaundice-like colour of the skin except for the sclerae, a fundamental element in the differential diagnosis with respect to liver disease. Free radicals, produced in oxidative reactions, are notoriously highly reactive and instable fragments of molecules, classified as ROS, reactive oxygen species, and RNS, reactive nitrogen species. Damage caused by free radicals includes disruption of the structure and functionality of cell membranes, in infinitesimal fractions of a second the rupture of molecules, the formation of new bonds, the oxidation of membrane phospholipids with alteration of membrane fluidity and permeability. The degradation of lipids by free radicals is shown by the presence of end products of advanced lipoxylation such as malondialdehyde. Free radicals can also act on mitochondria, modify amino acids, proteolysis of cytosolic proteins, damage enzymes, create cross bonds and aggregation between proteins, degrade nucleic acids with rupture of single and double filaments forming alternative nitrogen bases with alteration of the genetic information and of the physiological mechanisms of transcription, translation and replication. The extent and severity of the damage caused by free radicals are considerably limited and countered by the antioxidant properties of the DBM solution, in synergy with Melatonin (Igielska-Kalwat *et al.* 2015). The anticancer mechanisms of action of Betacarotene include maintaining the physiological levels of Glutathione, which rapidly decreases in the presence of tumors, and the protective-antitoxic effect by countering the lipid peroxidation increase due to the progress of the tumor (Basu *et al.* 2000).

Vitamins are physiological catalyzers between energy and matter. Any change in living matter must be accompanied by an adjustment in energy. Only slight quantitative variations in the production and absorption, i.e. processing, of the biological terrain and its energy equivalent are compatible with life, and reactions must therefore take place in gradual stages with minimal amounts of matter-energy, mutually compensated over time. These reactions lead very gradually to the production and absorption of energy and matter. This continuous process must, for the exceptional purposes, be gradually modulated and finely adjusted, and this would be impossible without vitamins, whose purpose is to condition and regulate the matter/energy equilibrium on which life is balanced. A complete knowledge of vitamins means knowledge of the finest equilibria, energy/matter relationships and all the effects on vital activities. Knowing the chemical composition, the formation, the localization inside the cell, the time of their intervention, and the regulation and extent of their activity makes it possible to understand the essence of physiological life and to correct patho-



logical deviations. Thus, from the original biochemical-vital role, vitaminology is raised in the DBM solution to a rational and essential role in the prevention and cure of various diseases. The study and in-depth knowledge of the regulatory mechanisms of normal physiological life thus permits the realization of effective countermeasures to prevent and/or contrast degenerative and/or neoplastic deviations. In tumor-predisposing situations and in neoplastic diseases, especially during chemo-radiotherapy, the structure and potential of cell membranes, and consequently receptorial expression and functionality, can be disrupted, with aggravation of oxidative processes and a consequent peak in the production of free radicals (Odeleye *et al.* 1992; Elangovan *et al.* 2008; Launoy *et al.* 1998; Shimizu *et al.* 2004; Di Bella, 2005; Neuzil *et al.* 2002; Frei & Lawson 2008). The DBM solution supplies apolar components such as Betacarotene and vit. E to the phospholipids of the cell membranes, stabilizing them and preserving them from oxidative damage and from free radicals (Shklar & Schwartz 1996; Israel *et al.* 2000; Kini *et al.* 2001; Di Bella, 2005; Dong *et al.* 2008; Lubin *et al.* 2008; Nesaret-nam 2008; Watters *et al.* 2009).

### **FUNCTIONS OF BETACAROTENE:**

- It has a protective effect on cell membranes (Di Bella 1998);
- It decreases lipid peroxidation and increases Glutathione (Basu *et al.* 2000);
- It has a direct antiproliferative effect (regardless of the conversion to ATRA) on tumor cells, it significantly suppresses both the mobility measured by means of tetrazolium MTT) and the synthesis of DNA (controlled by capitation of 3H-thymidine) and cell proliferation (measured by means of cell count) (Onogi *et al.* 1998).

### **FUNCTIONS OF RETINOIC ACID (ALL TRANS RETINOIC ACID –A.T.R.A.):**

- It acts by redifferentiating blast and tumor cells (Hassan *et al.* 1990);
- It triggers the synthesis of leukotriene C4 (Abe *et al.* 2003);
- It suppresses the gene transcription of oncogenic factors and promotes the antiproliferative effect (Arnold *et al.* 1994);
- It has an anti-angiogenetic action (Majewski *et al.* 1994);
- It reduces the microvascular density of the bone marrow in leukemia and of hot point density. It interrupts the production of VEGF by NB4 cells, suppressing angiogenesis (Kini *et al.* 2001);
- It stops the cell development associated with the increase in levels of interferon 1 [IRF-1] with activation of p21WAF1 (Arany *et al.* 2003);

- It activates apoptosis, with the contribution of IRF-1 and STAT1, by means of caspase 1 (Arany *et al.* 2003);
- It stops the progression of the cell cycle (Wu *et al.* 2009);
- It stops the cell cycle in G0/G1 (Wu *et al.* 2009);
- It triggers the expression of p21 WAF1/CIP 1, by means of p 53-dependent and independent pathways (Wu *et al.* 2009);
- In tumor cells, it inhibits the activation of AP-1 by means of its RAR-alpha receptor and suppresses the expression of cJun and cFos (Wu *et al.* 2009);
- It synergizes the effect of Bcl-2, both on growth arrest and expression of the p21 gene (Chou *et al.* 2000);
- It prevents the invasion of colon cancer cells and decreases the expression of matrilysin (Adachi *et al.* 2001);
- In tumor cells, it causes morphological and biochemical changes, such as membrane shrinkage, chromatin condensation and DNA splitting, typical characteristics of cells during apoptosis (Lee *et al.* 2008);
- By means of RAR-beta it leads to a net increase of c-myc and Bax proteins, with greater susceptibility to apoptosis (Lee *et al.* 2008);
- It decreases the potential of neoplastic proliferation and has an important role in differentiation, apoptosis and cell adhesion (Voigt *et al.* 2000);
- It makes tumor cells particularly sensitive to chemotherapy, also causing an increase in inter-cell communication in the gap junctions (Carystinos *et al.* 2001);
- It reduces the level of glial fibrillary protein and the synthesis of DNA, and induces apoptosis, demonstrating considerable synergism and reinforcement of the efficacy with TNF-alpha by increasing the receptors of p55 TNF (Chambaut-Guérin 2000);
- It induces a gene, autotaxin [ATX], which decodes a stimulation factor of tumor motility (Dufner-Beattie *et al.* 2001);
- It induces neurotic differentiation with extensive neurite growth, and a decrease of the oncoprotein n-Myc and of the mRNA of Gap-43. It exerts an antiproliferative effect by increasing the kinase A of the type II/RII beta protein and kinase A of the W protein (Kim *et al.* 2010);
- It differentiates tumor cells through its effect on A2, Ca<sup>2+</sup>-dependent phospholipases (Antony *et al.* 2001);
- It reduces the expression of VnR, correlated with the organisation of fibronectin and cell adhesion and expansion (Baroni *et al.* 2003);
- It reduces the inhibition chemically induced by RAR Beta, blocking the cell cycle in the G1 phase (Song *et al.* 2001);
- It reduces tumor invasiveness, by inhibiting matrix metalloproteinase (MMP). (Pham *et al.* 2013);
- It increases the activity of P 53 (Lu *et al.* 2000);



- Together with Vit D, it promotes apoptosis (Sha *et al.* 2013);
- It counters the hepatotoxic effect of chemotherapy (Ewees *et al.* 2015);
- It inhibits the inactivation of caspases (Piedrafita & Pfahl 1997; Takada *et al.* 2001; Jiang 2008);
- It inhibits the expression of BCOM1 associated with an increase colon cancer cell mobility and invasivity and inhibits the expression of MMP7 and MMP28, with an antiproliferative and antimetastatic effect (Pham *et al.* 2013).

## FUNCTIONS OF VITAMIN A

The use of vitamin A in the prevention and treatment of tumors, started more than 30 years ago by prof. Di Bella, is also well documented in the international scientific literature. Piedrafita (Piedrafita & Pfahl 1997) reported the induction of apoptosis caused by vitamin A and retinoids, through activation of proteolytic cell enzymes, the caspases. The degradation of the general transcription factor Sp-1 causes tumor cell death by apoptosis. There are numerous studies on the anticancer prevention activity of vit. A (Hennekens 1986; Kelloff *et al.* 1996; Lippman & Meyskens 1988; Redlich *et al.* 1995; Thiberville *et al.* 1996). A detailed review of the anticancer effects of vitamin A can also be found in the publications by Israel *et al.* 1980, and Pozzi *et al.* 1985. Samet *et al.* (Samet *et al.* 1985) carried out an epidemiological study, showing that a deficiency of vitamin A favours the development of lung cancer (Mettlin 1984; Barthet *et al.* 1989; Moon *et al.* 1994).

## FUNCTIONS OF VITAMIN E

It inhibits the growth of various tumor cells, such as:

- Prostate cancer cells (Israel *et al.* 2000; Yu *et al.* 2002; Zhang *et al.* 2002);
- Breast cancer cells (Yu *et al.* 1999)
- Lung cancer cells (Neuzil *et al.* 2001);
- Parotid cancer cells (Prasad *et al.* 1996);
- Stomach cancer cells (Rose & McFadden 2001; Wu *et al.* 2002);
- Colon cancer cells (Neuzil *et al.* 2001);
- Pancreatic cancer cells (Heisler *et al.* 2000);
- Oral squamous cell cancer (Elattar & Virji 1999);
- Melanoma cells (Prasad *et al.* 1990);
- Neuroblastoma cells (Prasad *et al.* 2003);
- Glioma cells (Prasad *et al.* 2003);
- Leukemia cells (Yamamoto *et al.* 2000);
- Lymphoma cells (Turley *et al.* 1995; Yu *et al.* 1997; Dalen & Neuzil 2003);
- At low doses it induces differentiation and inhibition of tumor proliferation; at higher concentrations it induces apoptosis (Prasad *et al.* 2003);
- Suppression of tumor growth (Prasad 2003);
- Apoptotic and/or cytostatic activity of breast cancer cells (Malafa & Neitzel 2000);

- Colon cancer cells (Prasad *et al.* 2003);
- Melanoma cells (Malafa & Neitzel 2002);
- Neuroblastoma cells (Prasad *et al.* 2003);
- Lymphoma cells (Sarna *et al.* 2000);
- It reinforces the anticancer action of various chemotherapy agents such as adriamycin, cisplatin and tamoxifen (Ripoll *et al.* 1986; Prasad *et al.* 1994);
- It protects bone marrow cells from the lethal effects of doxorubicin (Fariss *et al.* 1994);
- It reinforces the anticancer action of various chemotherapy agents, protecting healthy cells from toxic effects (Prasad *et al.* 2003)
- Antiangiogenic activity (Shklar & Schwartz 1996; Tang & Meydani 2001; Neuzil *et al.* 2002; Inokuchi *et al.* 2003; Miyazawa *et al.* 2004).

Retinoids are molecules with a hydrophobic structure, able to cross the biological membranes and to directly reach the nucleus where, interacting with specific nuclear receptors, they can exert their biological activity; retinoids are also often bound to proteins both inside cells and in the extracellular compartment, such proteins being known as RBPs: Retinoid Binding Proteins. The All Trans Retinoic Acid (ATRA) enters the cells by simple diffusion or by means of conversion from retinol (vitamin A) which has been absorbed in the gastrointestinal tract. Inside the cell, ATRA binds to specific proteins, the CRABPs (Cellular Retinoic Acid Binding Proteins), only two types (I and II) of which are known so far. The function of these proteins is still not clear although they could act as a system for the accumulation and transport of retinoids in particular intracellular compartments (e.g. the endoplasmatic reticulum for oxidation or the nucleus for interaction with specific receptors). The encoding gene for the CRABP-II protein presents two elements sensitive to retinoic acid and it appears that this gene can for this reason be induced by ATRA. In fact, subjects treated with ATRA present an increased expression of CRABP-II. The cells which produce this protein after administration of ATRA have not yet been identified. The ubiquitary receptorial expression of retinoids, RAR alfa beta gamma, and RXR alfa beta gamma, has been shown both at cell membrane and cell nucleus level, where RXR and RAR dimerize with vitamin D receptors (VDR) and RZR and ROR of Melatonin (components of the DBM), amplifying a dynamic differentiating and antiproliferative gene expression.

## RETINOID RECEPTORS

Two families of retinoid receptors have been identified so far:

- **RARs** (Retinoic Acid Receptors), of which we know three types (a, b and g) and various subtypes (a1, a2, b1-4, g1 and g2); these receptors bind ATRA and 9-cis retinoic acid.
- **RXRs** (Retinoid X Receptors) of which we know three types (a, b and g) which bind only 9-cis retinoic acid.

These receptors belong to a large superfamily of inducible nuclear receptors (which are also transcription factors) like steroid receptors, thyroid hormone receptors, vitamin D<sup>3</sup> receptors, *Drosophila* ecdysteroid receptors, and a number of receptors whose ligands have not yet been identified ("orphan" receptors). This superfamily can in turn be divided into two main families of nuclear receptors:

- steroid receptor family;
- non-steroid receptor family (thyroid hormones/retinoids/vitamin D).

The characteristic common to all these receptors is the ability to interact with regulatory regions of DNA called target sequences Hormone Response Elements (HREs) and to induce the transcription of specific genes. The structure of these receptors is extremely complex in relation to the functions they perform: several functional domains have in fact been identified in the context of these molecules. In the retinoid receptors, a total of 6 functional domains (A–F) have been identified in the RARs and only 5 (A–E) in the family of RXRs. A and B domains contain a transactivating region (activating gene transcription) defined AF-1, whose action inducing gene transcription is independent of the binding of the receptor with the ligand (retinoid). In the retinoid receptors there is also a second transactivating region (AF-2) present inside the domain which binds the ligand (domain E). In fact, RAR-a, -b and -g missing from the AF-2 region are unable to induce gene transcription. In an intact receptor, the function of binding with the ligand (domain E) and the transactivating function (region AF-2, also domain E) are clearly independent. Domain C functions as region for binding to DNA; it contains, in fact, two zinc-finger sequences capable of interacting with nucleotide sequences. The domains D and E contain a region implicated in the formation of dimers and a region implicated in the nuclear localization of the receptor.

### RARs

The RAR class consists of three types of receptors: RAR-a, RAR-b, and RAR-g. The members of this receptor family exhibit a distinct tissue and cell expression; they share a high degree of homology in the DNA binding domains (domain C) and ligand binding domains (domain E); they bind ATR and 9-cis retinoic acid with high affinity and 13-cis retinoic acid with low affinity. Each type of RAR (a, b or g) can in turn present different subtypes (a1, a2, b1-4, g1 and g2). The synthesis of different subtypes depends on two main mechanisms:

- **alternative transcription** due to the presence of two promoters in the framework of the same encoding gene: these transcripts generate receptor subtypes with different A domains and with different nucleotide sequence binding abilities;
- **alternative splicing.**

The RARs present 6 domains (A–F) from the N-terminal to the C-terminal. Until 1988 it was thought that

RARs, like thyroid hormone receptors (TRs), functioned exclusively as homodimers (RAR/RAR and TR/TR). It was subsequently shown that these receptors, like the vitamin D receptor (VDR), interact with other factors present in nuclear extracts to bind specific gene sequences with high affinity. After the discovery of RXRs, a series of laboratory experiments showed that these factors were in fact the RXRs, able to form heterodimers with the RARs, VDRs and TRs. The RAR-a is mainly expressed in the cerebellum, adrenal gland, testicles and leukemic cells of the myeloid line.


### RXRs

This family of receptors is only distantly correlated with the RAR family as regards the peptide sequence and seems unable to bind ATRA with high affinity. The ligand of RXRs is 9-cis retinoic acid, an isomer of ATRA that can interact with RXRs and RARs. RXR-a/RAR-a heterodimers bind to specific sequences of DNA known as Retinoic Acid Response Elements (RARE) which are two repeated sequences: Direct Repeats (DR) of the 5'-PuG(G/T)TCA (Pu: purine) type separated by 1–5 pairs of bases (DR1-5) and usually localized in the promoter region of a target gene. In addition to the DR sequences, there are other nucleotide sequences that the nuclear receptors bind to, like the IR sequences (Inverted Repeats), which are activated by TRs, RARs and RXRs, and the ER sequences (Everted Repeats). The binding of the ligand to the dimer complex RAR/RXR involves its interaction with DR sequences, which leads to control of the transcription (activation or suppression) of the gene downstream of the interaction site. Several studies suggest that the differentiation of myeloid lines induced by ATRA is in fact mediated by RAR-a/RXR-a heterodimer complexes and not through the activity of RAR-a (RAR-a/RAR-a) homodimer complexes.

In support of this, experiments carried out on HL60 cell lines show that RXRs are functional but not RARs as the latter are incapable of differentiating in response to ATRA. HL-60 cells resistant to the action of ATRA contain a non-sense mutation inside the region encoding for RAR-a; when transfected with a cDNA vector encoding for RAR-a, the cells can easily differentiate in response to ATRA. Dawson and Xia showed that, by using synthetic ligands for the pairs of RAR/RXR and RXR/RXR, the differentiation of the myeloid line depends almost exclusively on the action of the heterodimer RARs/RXRs (Dawson & Xia 2012; Di Masi *et al.* 2015; Eroglu & Harrison 2012; Long *et al.* 2015; Urvalek *et al.* 2014; Zhong *et al.* 2013).

After binding to RAR/RXZ, the retinoids modulate the expression of genes involved in programmed cell death (apoptosis) through inhibition of Bcl2 and consequent caspase activation.

They also have an antiproliferative effect with activation of P21/P27, and a consequent halt in the cell cycle in the G0/G1 stages, and a protective action at the level



The cell membrane (in pale blue) containing the phospholipid layer (in red) is a defence, a vital filter through which everything passes, from inside the cell towards the exterior, where the stimuli and the conditioning from the exterior towards the interior and vice versa are assimilated, in which communication takes place, where impulses and signals are emitted and received. Optimizing it, making it efficient, means making the cell able to defend itself in ideal conditions, reinforcing it: Vit. E and Betacarotene protect and stabilize the membrane, MLT physiologically modulates its potentials, regulating the ion channels and all the dynamic ands and receptorial expression.

of the cell membrane, in total synergy with ascorbic acid, tocopherol and melatonin.

Vitamin E induces neoplastic apoptotic also through externalization of phosphatidylserine from the membrane of tumor cells and relative chemotaxis of cell immunity.



## CONCLUSIONS

THE LITERATURE HAS EXTENSIVELY DOCUMENTED AND CONFIRMED THE DETERMINING ROLE OF RETINOIDS IN THE PREVENTION AND THERAPY OF TUMORS, AS SUMMARIZED BELOW



**Interaction and factorial synergism of retinoid with vitamin E and other components of the DBM** (Barroga *et al.* 2000; Black 2013; Suarez *et al.* 2014; Watters *et al.* 2009; Gilbert *et al.* 2012; Hu *et al.* 2014).

**Antioxidant, antiradical and antitoxic activity preventing tumor development** (Buring *et al.* 1994; Clamon 1980; Connolly *et al.* 2013; Den Hollander *et al.* 2013; Doldo *et al.* 2015; Helm *et al.* 2013; Ianhez *et al.* 2013; Jeon *et al.* 2011; Kabat *et al.* 2012; Miyanishi *et al.* 2015; Jiang 2014; Mondul *et al.* 2013; Siems *et al.* 2009; Tanaka *et al.* 2012; Virtamo *et al.* 2014; Wang *et al.* 2014; Igielska-Kalwat *et al.* 2015; Li *et al.* 2012).

**Apoptotic, cytostatic, and antiproliferative properties:** Retinoids inhibit mutagenesis through a pro-differentiating action, keeping the healthy cells “differentiated”, they favour the reversion to normality and redifferentiate cells that tend to become







or are already “indifferentiated” and neoplastic. The alteration of the GF-TRK ligand-receptor system and the altered response to the differentiating stimulus are also effectively countered by the retinoids. (Arany *et al.* 2003; Basu *et al.* 2000; Chang *et al.* 2013; Constantinou *et al.* 2012; Cui *et al.* 2007; Dalen & Neuzil 2003; Dong *et al.* 2008; Ginestier *et al.* 2009; Gudas 2013; Lim *et al.* 2014; Lu *et al.* 2013; Neuzil *et al.* 2001; Onogi *et al.* 1998; Piedrafita & Pfahl 1997; Voigt *et al.* 2000; Yang *et al.* 2012; Yin *et al.* 2009; Wu *et al.* 2009).

**Antiangiogenic properties:** Retinoids inhibit angiogenesis in tumor tissues in synergy and interaction with other components of the DBM, such as Vitamins D and C, GH inhibitors and GH-dependent growth factors, D2 receptor agonists (Malafa *et al.* 2002; Inokuchi *et al.* 2003; Majewski *et al.* 1994; Miyazawa *et al.* 2004; Siveen *et al.* 2014; Tang & Meydani 2001).

**Antimetastatic properties, by activating intercellular adhesion and inhibition of cell passage through the natural containment barriers of metastatic invasion such as the EMC, preventing lysis** (Adachi *et al.* 2001; Lee *et al.* 2014; Lim *et al.* 2013; Lotan *et al.* 1991; Pham *et al.* 2013; Siddikuzzaman, Grace, 2012; Siddikuzzaman *et al.* 2012; Walder *et al.* 1997).

**Immunostimulating properties of retinoids in the natural immunity and response of NK cells, improvement of the functionality of organs and tissues with increase of cell trophism, particularly evident at epithelial level** (Carratù *et al.* 2012; Ding *et al.* 2013; Han *et al.* 2014; Lo *et al.* 2014; Pekmezci 2011; Prabhala *et al.* 1991).

## REFERENCES

- Vol. 113 of the Ciba Foundation Symposia (1985). Studies on the mechanism of retinoid-induced pattern duplications in the early chick limb bud: temporal and spatial aspects. *J Cell Biol.* **101**(5): 1913–1920.
- Abe M, Shibata K, Urata H, Sakata N, Katsuragi T (2003). Induction of leukotriene C4 synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and a low dose of actinomycin D and its suppression with methylprednisolone. *J Cell Physiol.* **196**(1): 154–64.
- Adachi Y, Itoh F, Yamamoto H, Iku S, Matsuno K, Arimura Y, Imai K (2001). Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. *Tumour Biol.* **22**(4): 247–53.
- Al-Malki AL, Moselhy SS (2013). Protective effect of vitamin E and epicatechin against nicotine-induced oxidative stress in rats. *Toxicol Ind Health.* **29**(2): 202–8. See comment in PubMed Commons below. *Cancer Res.*
- Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA (2014). Retinoids and their biological effects against cancer. *Int Immunopharmacol.* **18**(1): 43–9.
- Álvarez R, Vaz B, Gronemeyer H, de Lera ÁR (2014). Functions, therapeutic applications, and synthesis of retinoids and carotenoids. *Chem Rev.* **114**(1): 1–125.
- Angulo-Molina A, Reyes-Leyva J, López-Malo A, Hernández J (2014). The role of alpha tocopheryl succinate (α-TOS) as a potential anticancer agent. *Nutr Cancer.* **66**(2): 167–76.
- Antony P, Freysz L, Horrocks LA, Farooqui AA (2001). Effect of retinoic acid on the Ca<sup>2+</sup>-independent phospholipase A2 in nuclei of LA-N-1 neuroblastoma cells. *Neurochem Res.* **26**(1): 83–8.
- Arany I, Ember IA, Tying SK (2003). All-trans-retinoic acid activates caspase-1 in a dose-dependent manner in cervical squamous carcinoma cells. *Anticancer Res.* **23**(1A): 471–3.
- Arnold A, *et al.* (1994). Phase III trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. *J Natl Cancer Inst.* **86**(4): 306–309.

*“There is nor ever will be a cytotoxic chemotherapy treatment that can cure a solid tumor, but only a method, a rational and biological multitherapy, a complex of synergic and factorially interactive substances, individually having atoxic anticancer activity, which sequentially or simultaneously act centripetally on the myriad of biological reactions of tumor life, gradually restoring the vital reactions deviated by the tumor to normality.”*

LUIGI DI BELLA.



- 11 Baroni A, Paoletti I, Silvestri I, Buommino E, Carriero MV (2003). Early vitronectin receptor downregulation in a melanoma cell line during all-trans retinoic acid-induced apoptosis. *Br J Dermatol.* **148**(3): 424–33.
- 12 Barroga EF, Kadosawa T, Okumura M, Fujinaga T (2000). Influence of vitamin D and retinoids on the induction of functional differentiation in vitro of canine osteosarcoma clonal cells. *Vet J.* **159**(2): 186–93.
- 13 Barthelet M, *et al.* (1989). Vitamins A and E in digestive cancers. *Acad Sci III.* **309**(4): 101–104. French.
- 14 Basu M, Banerjee A, Bhattacharya UK, Bishayee A, Chatterjee M (2000). Beta-carotene prolongs survival, decreases lipid peroxidation and enhances glutathione status in transplantable murine lymphoma. *Phytomedicine.* **7**(2): 151–9.
- 15 Black HS (2013). Hemoglobin. Interaction of ascorbic acid and tocopherol on beta-carotene modulated carcinogenesis. *Arch Biochem Biophys.* **539**(2): 230–8.
- 16 Brun PJ, Yang KJ, Lee SA, Yuen JJ, Blaner WS (2013). Retinoids: Potent regulators of metabolism. *Biofactors.* **39**(2): 151–63.
- 17 Buring JE, *et al.* (1994). The alpha-tocopherol, beta-carotene lung cancer prevention trial of vitamin E and beta-carotene: the beginning of the answers. *Ann Epidemiol.* **4**(1): 75.
- 18 Carratù MR, Marasco C, Mangialardi G, Vacca A (2012). Retinoids: novel immunomodulators and tumour-suppressive agents? *Br J Pharmacol.* **167**(3): 483–92.
- 19 Carystinos GD, Alaoui-Jamali MA, Phipps J, Yen L, Batist G (2001). Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells. *Cancer Chemother Pharmacol.* **47**(2): 126–32.
- 20 Chambaut-Guérin AM (2000). Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells. *Neuroreport.* **11**(2): 389–93.
- 21 Chang J, Thangamani S, Kim MH, Ulrich B, Morris SM Jr, Kim CH (2013). Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation. *Eur J Immunol.* **43**(4): 967–78.
- 22 Chen MC, Hsu SL, Lin H, Yang TY (2014). Retinoic acid and cancer treatment. *Biomedicine (Taipei).* **4**: 22. Epub 2014 Nov 28.
- 23 Chou HK, Chen SL, Hsu CT, Chao YC, Tsao YP (2000). Bcl-2 accelerates retinoic acid-induced growth arrest and recovery in human gastric cancer cells. *Biochem J.* **348** Pt 2: 473–9.
- 24 Clamon GH (1980). Retinoids for the prevention of epithelial cancers: current status and future potential. *Med Pediatr Oncol.* **8**(2): 177–185. Review.
- 25 Connolly RM, Nguyen NK, Sukumar S (2013). Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. *Clin Cancer Res.* **19**(7): 1651–9.
- 26 Constantinou C, Neophytou CM, Vraka P, Hyatt JA, Papas KA, Constantinou AI (2012). Induction of DNA damage and caspase-independent programmed cell death by vitamin E. *Nutr Cancer.* **64**(1): 136–52.
- 27 Cui Y, Lu Z, Bai L, Shi Z, Zhao WE, Zhao B (2007). beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells. *Eur J Cancer.* **43**(17): 2590–601. Epub 2007 Oct 1.
- 28 Dalen H, Neuzil J (2003). Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. *Br J Cancer.* **88**(1): 153–8.
- 29 Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, Verma A, Ray SK, Evans T (2014). Retinoic acid signaling pathways in development and diseases. *Bioorg Med Chem.* **22**(2): 673–83.
- 30 Dawson MI, Xia Z (2012). The retinoid X receptors and their ligands. *Biochim Biophys Acta.* **1821**(1): 21–56.
- 31 Den Hollander P, Savage MI, Brown PH (2013). Targeted therapy for breast cancer prevention. *Front Oncol.* **3**: 250.
- 32 Di Bella G, Colori B, Mascia F (2012). The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of lymphomas. *Neuro Endocrinol Lett.* **33**(8): 773–81.
- 33 Di Bella G, Colori B (2012). The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck. *Neuro Endocrinol Lett.* **33**(3): 249–56.
- 34 Di Bella G, Mascia F, Colori B (2013). The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature. *Neuro Endocrinol Lett.* **34**(6): 523–8.
- 35 Di Bella G, Mascia F, Gualano L, Di Bella L (2013). Melatonin anti-cancer effects: review. *Int J Mol Sci.* **14**(2): 2410–30.
- 36 Di Bella G, Mascia F, Ricchi A, Colori B (2013). Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report. *Neuro Endocrinol Lett.* **34**(7): 660–8.
- 37 Di Bella G (2005). *Il Metodo Di Bella*, Mattioli Editore, 3° Edizione.
- 38 Di Bella G (2010). The Di Bella Method (DBM). *Neuro Endocrinol Lett.* **31** Suppl 1: 1–42. Review.
- 39 Di Bella G (2011). The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer. *Neuro Endocrinol Lett.* **32**(6): 751–62.
- 40 Di Bella L *et al.* (1979). Perspectives in Pineal functions. *Progress in Brain Research*, vol.52, Elsevier Publ. Co. Amsterdam.
- 41 Di Bella L *et al.* (1997). Melatonina dalla ricerca agli interventi – Atti del convegno – Reggio Calabria.
- 42 Di Bella L, Gualano L (2006). Key aspects of melatonin physiology: thirty years of research. *Neuro Endocrinol Lett.* **27**(4): 425–432.
- 43 Di Bella L (1998). Cancro: siamo sulla strada giusta? Travel factory.
- 44 Di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C, Lo-Coco F, Ascenzi P, Nervi C (2015). Retinoic acid receptors: from molecular mechanisms to cancer therapy. *Mol Aspects Med.* **41**: 1–115.
- 45 Ding W, Shimada H, Li L, Mittal R, Zhang X, Shudo K, He Q, Prasadara NV, Wu L (2013). Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model. *Blood.* **121**(6): 996–1007. Epub 2012 Dec 13.
- 46 Doldo E, Costanza G, Agostinelli S, Tarquini C, Ferlosio A, Arcuri G, Passeri D, Sciolli MG, Orlandi A (2015). Vitamin A, Cancer Treatment and Prevention: The New Role of Cellular Retinol Binding Proteins. *Biomed Res Int.* **2015**: 624627. Epub 2015 Mar 24. Review.
- 47 Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK, Freeman R, Swettenham E, Valis K, Liu J, Zabolova R, Turanek J, Spitz DR, Domann FE, Scheffler IE, Ralph SJ, Neuzil J (2008). Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. *Oncogene.* **27**(31): 4324–35. Epub 2008 Mar 31.
- 48 Dufner-Beattie J, Lemons RS, Thorburn A (2001). Retinoic acid-induced expression of autotaxin in N-myc-amplified neuroblastoma cells. *Mol Carcinog.* **30**(4): 181–9.
- 49 Elangovan S, Hsieh TC, Wu JM (2008). Growth inhibition of human MDA-MB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product. *Anticancer Res.* **28**(5A): 2641–7.
- 50 Elattar TM, Virji AS (1999). Biphasic action of vitamin E on the growth of human oral squamous carcinoma cells. *Anticancer Res.* **19**(1A): 365–8.
- 51 Eroglu A, Harrison EH (2013). Carotenoid metabolism in mammals, including man: formation, occurrence, and function of apocarotenoids. *J Lipid Res.* **54**(7): 1719–30.

- 52 Eroglu A, Hruszkewycz DP, dela Sena C, Narayanasamy S, Riedl KM, Kopec RE, Schwartz SJ, Curley RW Jr, Harrison EH (2012). Naturally occurring eccentric cleavage products of provitamin A  $\beta$ -carotene function as antagonists of retinoic acid receptors. *J Biol Chem.* **287**(19): 15886–95.
- 53 Ewees MG, Abdelghany TM, Abdel-Aziz AA, Abdel-Bakky MS (2015). All-trans retinoic acid mitigates methotrexate-induced liver injury in rats; relevance of retinoic acid signaling pathway. *Naunyn Schmiedebergs Arch Pharmacol.* **388**(9): 931–8.
- 54 Fariss MW, Fortuna MB, Everett CK, Smith JD, Trent DF, Djuric Z (1994). The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds. *Cancer Res.* **54**(13): 3346–51.
- 55 Flajollet S, Staels B, Lefebvre P (2013). Retinoids and nuclear retinoid receptors in white and brown adipose tissues: physiopathologic aspects. *Horm Mol Biol Clin Investig.* **14**(3): 75–86.
- 56 Franke AA, Morrison CM, Custer LJ, Li X, Lai JF (2013). Simultaneous analysis of circulating 25-hydroxy-vitamin D3, 25-hydroxy-vitamin D2, retinol, tocopherols, carotenoids, and oxidized and reduced coenzyme Q10 by high performance liquid chromatography with photo diode-array detection using C18 and C30 columns alone or in combination. *J Chromatogr A.* **1301**: 1–9.
- 57 Frei B, Lawson S (2008). Vitamin C and cancer revisited. *Proc Natl Acad Sci U S A.* **105**(32): 11037–8.
- 58 Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM (2012). Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer: diagnosis, stage, and grade. *Cancer Causes Control.* **23**(11): 1865–73.
- 59 Ginestier C, Wicinski J, Cervera N (2009). Retinoid signaling regulates breast cancer stem cell differentiation. *Cell Cycle.* **8**(20): 3297–302.
- 60 Goodman DS, Huang HS, Kanai M, Shiratori T (1967). The enzymatic conversion of all-trans  $\beta$ -carotene into retinal in *J. Biol. Chem.* **242**: 3543–3554.
- 61 Gudas LJ (2013). Retinoids induce stem cell differentiation via epigenetic changes. *Semin Cell Dev Biol.* **24**(10–12): 701–5.
- 62 Han RM, Cheng H, Feng R, Li DD, Lai W, Zhang JP, Skibsted LH (2014).  $\beta$ -Carotene As a Lipophilic Scavenger of Nitric Oxide. *J Phys Chem B.* **118**(40): 11659–66.
- 63 Hassan IB, Hagberg H, Sundström C (1990). Immunophenotype of hairy-cell leukemia. *Eur J Haematol.* **45**(3): 172–6.
- 64 Heisler T, Towfigh S, Simon N, Liu C, McFadden DW (2000). Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth. *J Surg Res.* **88**(1): 23–5.
- 65 Helm CW, Lorenz DJ, Meyer NJ, Rising WW, Wulff JL (2013). Retinoids for preventing the progression of cervical intra-epithelial neoplasia. *Cochrane Database Syst Rev.* **6**: CD003296.
- 66 Hennekens CH (1986). Vitamin A analogues in cancer chemoprevention. in: VT DeVita Jr, S Hellman, SA Rosenberg (Eds.) *Important Advances in Oncology*. Lippincott, Philadelphia, 23–35.
- 67 Hinds TS, *et al.* (1989). Carotenoids and retinoids: a review of research, clinical, and public health applications. *J Clin Pharmacol.* **199737**(7): 551–558. Review.
- 68 Hu J, Qi Q, Zhang Y (2014). Comparative research for the dietary pattern of patients with esophageal cancer at different developing stages and the daily intake of vitamin A, E and  $\beta$ -carotene. *Pak J Pharm Sci.* **27**(4 Suppl): 1093–8.
- 69 Ianhez M, Fleury LF Jr, Miot HA, Bagatin E (2013). Retinoids for prevention and treatment of actinic keratosis. *An Bras Dermatol.* **88**(4): 585–93.
- 70 Igielska-Kalwat J, Gościńska J, Nowak I (2015). Carotenoids as natural antioxidants. *Postepy Hig Med Dosw (Online).* **69**: 418–28. Review. Polish.
- 71 Inokuchi H, Hirokane H, Tsuzuki T, Nakagawa K, Igarashi M, Miyazawa T (2003). Anti-angiogenic activity of tocotrienol. *Biosci Biotechnol Biochem.* **67**(7): 1623–7.
- 72 Israel L, *et al.* (1980). Vitamin A and cancer. *Pathos Biol (Paris).* **28**(4): 253–259. Review. French.
- 73 Israel K, Yu W, Sanders BG, Kline K (2000). Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. *Nutr Cancer.* **36**(1): 90–100.
- 74 Jeon YJ, Myung SK, Lee EH, Kim Y, Chang YJ, Ju W, Cho HJ, Seo HG, Huh BY (2011). Effects of beta-carotene supplements on cancer prevention: meta-analysis of randomized controlled trials. *Nutr Cancer.* **63**(8): 1196–207.
- 75 Jiang Q (2014). Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. *Free Radic Biol Med.* **72**: 76–90.
- 76 Jiang M, Zhu K, Grenet J, Lahti JM (2008). Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. *Biochim Biophys Acta.* **1783**(6): 1055–67.
- 77 Kabat GC, Kim MY, Sarto GE, Shikany JM, Rohan TE (2012). Repeated measurements of serum carotenoid, retinol and tocopherol levels in relation to colorectal cancer risk in the Women's Health Initiative. *Eur J Clin Nutr.* **66**(5): 549–54. Epub 2011 Dec 14.
- 78 Kelloff GJ, *et al.* (1996). New agents for cancer chemoprevention. *J Cell Biochem Suppl.* **26**: 1–28. Review.
- 79 Kim SH, Kim MK, Yu HS, Kim HS, Park IS, Park HG, Kang UG, Kim YS (2010). Electroconvulsive seizure increases phosphorylation of PKC substrates, including GAP-43, MARCKS, and neurogranin, in rat brain. *Prog Neuropsychopharmacol Biol Psychiatry.* **34**(1): 115–21.
- 80 Kini AR, Peterson LA, Tallman MS, Lingen MW (2001). Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. *Blood.* **97**(12): 3919–24.
- 81 Khuri FR, Kim ES, Lee JJ (2001). The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. *Cancer Epidemiol Biomarkers Prev.* **10**(8): 823–9.
- 82 Launoy G, Milan C, Day NE, Pienkowski MP, Gignoux M, Faivre J (1998). Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study. *Int J Cancer.* **76**(1): 7–12.
- 83 Lee HA, Lim JY, Kim Y, Jung CH, Yoo SH, Kim Y (2014).  $\beta$ -Carotene inhibits neuroblastoma cell invasion and metastasis in vitro and in vivo by decreasing level of hypoxia-inducible factor-1 $\alpha$ . *J Nutr Biochem.* **25**(6): 655–64.
- 84 Lee LT, Schally AV, Liebow C (2008). Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin. *Anticancer Res.* **28**(5A): 2599–605.
- 85 Leuenberger MG, Engeloch-Jarret C, Woggon WD (2001). The Reaction Mechanism of the Enzyme-Catalyzed Central Cleavage of beta-Carotene to Retinal. *Angew Chem Int Ed Engl.* **40**(14): 2613–2617.
- 86 Li G, Lee MJ, Liu AB, Yang Z, Lin Y, Shih WJ, Yang CS (2012). The antioxidant and anti-inflammatory activities of tocopherols are independent of Nrf2 in mice. *Free Radic Biol Med.* **52**(7): 1151–8.
- 87 Liede KE, Alfthan G, Hietanen JHP, Haukka JK, Saxen LM, Heinonen OP (1998). Beta-carotene concentration in buccal mucosal cells with and without dysplastic oral leukoplakia after long-term beta-carotene supplementation in male smokers. *European Journal of Clinical Nutrition.* **52**(12): 872–876.
- 88 Lim JY, Kim YS, Kim Y (2013).  $\beta$ -carotene Regulates the Murine Liver Microenvironment of a Metastatic Neuroblastoma. *J Cancer Prev.* **18**(4): 337–45.
- 89 Lim SW, Loh HS, Ting KN, Bradshaw TD, Zeenathul NA (2014). Cytotoxicity and apoptotic activities of alpha-, gamma- and delta-tocotrienol isomers on human cancer cells. *BMC Complement Altern Med.* **14**: 469.
- 90 Ling MT, Luk SU, Al-Ejeh F, Khanna KK (2012). Tocotrienol as a potential anticancer agent. *Carcinogenesis.* **33**(2): 233–9.
- 91 Lippman SM, Meyskens FL Jr (1988). Vitamin A derivatives in the prevention and treatment of human cancer. *J Am Coll Nutr.* **7**(4): 269–84. Review.

- 92 Lo HM, Wang SW, Chen CL, Wu PH, Wu WB (2014). Effects of all-trans retinoic acid, retinol, and  $\beta$ -carotene on murine macrophage activity. *Food Funct.* **5**(1): 140–8.
- 93 Long MD, Sucheston-Campbell LE, Campbell MJ (2015). Vitamin D receptor and RXR in the post-genomic era. *J Cell Physiol.* **230**(4): 758–66.
- 94 Lotan R, *et al.* (1991). Retinoids as modulators of tumor cells invasion and metastasis. *Semin Cancer Biol.* **2**(3): 197–208. Review.
- 95 Lu J, Zhang F, Yuan Y, Ding C, Zhang L, Li Q (2013). All-trans retinoic acid upregulates the expression of p53 via Axin and inhibits the proliferation of glioma cells. *Oncol Rep.* **29**(6): 2269–74.
- 96 Lu J, Mochhala S, Kaur C, Ling E (2000). Changes in apoptosis-related protein (p53, Bax, Bcl-2 and Fos) expression with DNA fragmentation in the central nervous system in rats after closed head injury. *Neurosci Lett.* **290**(2): 89–92.
- 97 Lubin JH, Virtamo J, Weinstein SJ, Albanes D (2008). Cigarette smoking and cancer: intensity patterns in the alpha-tocopherol, beta-carotene cancer prevention study in Finnish men. *Am J Epidemiol.* **167**(8): 970–5.
- 98 Majewski S, *et al.* (1994). Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines. *Int J Cancer.* **57**(1): 81–85.
- 99 Malafa MP, Fokum FD, Smith L, Louis A (2002). Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. *Ann Surg Oncol.* **9**(10): 1023–32.
- 100 Malafa MP, Neitzel LT (2000). Vitamin E succinate promotes breast cancer tumor dormancy. *J Surg Res.* **93**(1): 163–70.
- 101 Margheri M, Pacini N, Tani A, Nosi D, Squecco R, Dama A, Masala E, Francini F, Zecchi-Orlandini S, Formigli L (2012). Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. *Eur J Pharmacol.* **681**(1–3): 34–43. Epub 2012 Feb 21.
- 102 McLaren DS, Kraemer K (2012). Retinoids and carotenoids in general medicine. *World Rev Nutr Diet.* **103**: 137–47. Epub 2012 Aug 27. Review.
- 103 Mettlin C (1984). Epidemiologic studies on vitamin A and cancer. *Adv Nutr Res.* **6**: 47–65. Review.
- 104 Miyanishi K, Hoki T, Tanaka S, Kato J (2015). Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. *World J Hepatol.* **7**(3): 593–9.
- 105 Miyazawa T, Tsuzuki T, Nakagawa K, Igarashi M (2004). Antiangiogenic potency of vitamin E. *Ann NY Acad Sci.* **1031**: 401–4.
- 106 Mondul AM, Sampson JN, Moore SC, Weinstein SJ, Evans AM, Karoly ED, Virtamo J, Albanes D (2013). Metabolomic profile of response to supplementation with  $\beta$ -carotene in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *Am J Clin Nutr.* **98**(2): 488–93.
- 107 Moon RC (1994). Vitamin A, retinoids and breast cancer. *Adv Exp Med Biol.* **364**: 101–7. Review.
- 108 Nesaretnam K (2008). Multitargeted therapy of cancer by tocotrienols. *Cancer Lett.* **269**(2): 388–95.
- 109 Neuzil J, Zhao M, Ostermann G, Sticha M, Gellert N, Weber C, Eaton JW, Brunk UT (2002). Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. *Biochem J.* **362**(Pt 3): 709–15.
- 110 Neuzil, Weber T, Terman A, Weber C, Brunk UT (2001). Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role. *Redox Rep.* **6**(3): 143–51. Review.
- 111 Norsa A, Martino V (2006). Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status. *Cancer Biother Radiopharm.* **21**(1): 68–73.
- 112 Norsa A, Martino V (2007). Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. *Cancer Biother Radiopharm.* **22**(1): 50–5.
- 113 Odeleye OE, Eskelson CD, Mufti SI, Watson RR (1992). Vitamin E inhibition of lipid peroxidation and ethanol-mediated promotion of esophageal tumorigenesis. *Nutr Cancer.* **17**(3): 223–34.
- 114 Onogi N, Okuno M, Matsushima-Nishiwaki R, Fukutomi Y, Mori-waki H, Muto Y, *et al.* (1998). Antiproliferative effect of carotenoids on human colon cancer cells without conversion to retinoic acid. *Nutr Cancer.* **32**(1): 20–24.
- 115 Papadimitrakopoulou VA, Lee JJ, William WN Jr, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM (2009). Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. *J Clin Oncol.* **27**(4): 599–604. Epub 2008 Dec 15.
- 116 Pekmezci D (2011). Vitamin E and immunity. *Vitam Horm.* **86**: 179–215.
- 117 Pham DN, Leclerc D, Lévesque N, Deng L, Rozen R (2013).  $\beta$ , $\beta$ -carotene 15,15'-monooxygenase and its substrate  $\beta$ -carotene modulate migration and invasion in colorectal carcinoma cells. *Am J Clin Nutr.* **98**(2): 413–22.
- 118 Piedrafita FJ, Pfahl M (1997). Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. *Mol Cell Biol.* **17**(11): 6348–58.
- 119 Pozzi V, *et al.* (1985). Clinical use of vitamin A and E in gynecology. *Acta Vitaminol Enzymol.* **7** Suppl: 79–83. Italian.
- 120 Prabhala RH, *et al.* (1991). The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans. *Cancer.* **67**(6): 1556–1560.
- 121 Prasad KN, Cohrs RJ, Sharma OK (1990). Decreased expressions of c-myc and H-ras oncogenes in vitamin E succinate induced morphologically differentiated murine B-16 melanoma cells in culture. *Biochem Cell Biol.* **68**(11): 1250–5.
- 122 Prasad KN, Kumar B, Yan XD, Hanson AJ, Cole WC (2003). Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. *J Am Coll Nutr.* **22**(2): 108–17. Review.
- 123 Prasad KN, Kumar R (1996). Effect of individual and multiple antioxidant vitamins on growth and morphology of human nontumorigenic and tumorigenic parotid acinar cells in culture. *Nutr Cancer.* **26**(1): 11–9.
- 124 Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA (1994). Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. *Nutr Cancer.* **22**(3): 233–45.
- 125 Reboul E (2013). Absorption of vitamin A and carotenoids by the enterocyte: focus on transport proteins. *Nutrients.* **5**(9): 3563–81.
- 126 Redlich CA, *et al.* (1995). Vitamin A chemoprevention of lung cancer. A short-term biomarker study. *Adv Exp Med Biol.* **375**: 17–29. Review.
- 127 Ripoll EA, Rama BN, Webber MM (1986). Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. *J Urol.* **136**(2): 529–31.
- 128 Rose AT, McFadden DW (2001). Alpha-tocopherol succinate inhibits growth of gastric cancer cells in vitro. *J Surg Res.* **95**(1): 19–22.
- 129 Samet JM, *et al.* (1985). Lung cancer risk and vitamin A consumption in New Mexico. *Am Rev Respir Dis.* **131**(2): 196–202.
- 130 Sarna S, Kumar A, Bhola RK (2000). alpha-Tocopherol enhances tumour growth inhibition by cis-dichlorodiammine platinum (II). *Braz J Med Biol Res.* **33**(8): 929–36.
- 131 Sha J, Pan J, Ping P, Xuan H, Li D, Bo J, Liu D, Huang Y (2013). Synergistic effect and mechanism of vitamin A and vitamin D on inducing apoptosis of prostate cancer cells. *Mol Biol Rep.* **40**(4): 2763–8.
- 132 Shimizu S, Yasui C, Kawasaki H, Tsuchiya K (2004). Dramatic efficacy of oral aromatic retinoid in long-standing hypertrophic lupus erythematosus. *Acta Derm Venereol.* **84**(6): 491–2.
- 133 Shklar G, Schwartz JL (1996). Vitamin E inhibits experimental carcinogenesis and tumour angiogenesis. *Eur J Cancer B Oral Oncol.* **32B**(2): 114–9.
- 134 Siddikuzzaman, Grace VM (2012). Inhibition of metastatic lung cancer in C57BL/6 mice by liposome encapsulated all trans retinoic acid (ATRA). *Int Immunopharmacol.* **14**(4): 570–9.



- 135 Siddikuzzaman, Manjamalai A, Berlin Grace VM (2012). Chemo-protective effect of all-trans retinoic acid (ATRA) on oxidative stress and lung metastasis induced by, benzo(a)pyrene. *Immunopharmacol Immunotoxicol.* **34**(2): 317–25.
- 136 Siems W, Salerno C, Crifo C, Sommerburg O, Wiswedel I (2009). Beta-carotene degradation products - formation, toxicity and prevention of toxicity. *Forum Nutr.* **61**: 75–86. Epub 2009 Apr 7.
- 137 Siveen KS, Ahn KS, Ong TH, Shanmugam MK, Li F, Yap WN, Kumar AP, Fong CW, Tergaonkar V, Hui KM, Sethi G (2014). Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. *Oncotarget.* **5**(7): 1897–911.
- 138 Smith TAD (1998). Carotenoids and cancer: prevention and potential therapy. *British Journal of Biomedical Science.* **55**(4): 268–275.
- 139 Sommer A, Vyas KS (2012). A global clinical view on vitamin A and carotenoids. *Am J Clin Nutr.* **96**(5): 1204S–6S.
- 140 Song JI, Lango MN, Hwang JD, Drenning SD, Zeng Q, Lamph WW, Grandis JR (2001). Abrogation of transforming growth factor- $\alpha$ /epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. *Cancer Res.* **61**(15): 5919–25.
- 141 Suarez EC, Schramm-Sapota NL (2014). Race differences in the relation of vitamins A, C, E, and  $\beta$ -carotene to metabolic and inflammatory biomarkers. *Nutr Res.* **34**(1): 1–10.
- 142 Takada N, Isogai E, Kawamoto T, Nakanishi H, Todo S, Nakagawa A (2001). Retinoic acid-induced apoptosis of the CHP134 neuroblastoma cell line is associated with nuclear accumulation of p53 and is rescued by the GDNF/Ret signal. *Med Pediatr Oncol.* **36**(1): 122–6.
- 143 Takahashi N, Iwahori A, Breitman TR, Fukui (1997). Tunicamycin in combination with retinoic acid synergistically inhibits cell growth while decreasing palmitoylation and enhancing retinoylation of proteins in the human breast cancer cell line MCF-7. *T. Oncol Res.* **9**(10): 527–33.
- 144 Tanaka T, Shnimizu M, Moriwaki H (2012). Cancer chemoprevention by carotenoids. *Molecules.* **17**(3): 3202–42.
- 145 Tang FY, Meydani M (2001). Green tea catechins and vitamin E inhibit angiogenesis of human microvascular endothelial cells through suppression of IL-8 production. *Nutr Cancer.* **41**(1–2): 119–25.
- 146 Thiberville L, *et al.* (1996). Vitamin A derivatives and prevention of bronchial cancers, *Rev Mal Respir.* **13**(2): 193–195. Review. French.
- 147 Todisco M (2009). Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. *Cancer Biother Radiopharm.* **24**(3): 353–5.
- 148 Todisco M, Casaccia P, Rossi N (2001). Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial. *Cancer Biother Radiopharm.* **16**(2): 171–7.
- 149 Turley JM, Funakoshi S, Ruscetti FW, Kasper J, Murphy WJ, Longo DL, Birchenall-Roberts MC (1995). Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: role for transforming growth factor beta. *Cell Growth Differ.* **6**(6): 655–63.
- 150 Urvalek A, Laursen KB, Gudas LJ (2014). The roles of retinoic acid and retinoic acid receptors in inducing epigenetic changes. *Subcell Biochem.* **70**: 129–49.
- 151 Vilanova N, Solans C (2015). Vitamin A Palmitate- $\beta$ -cyclodextrin inclusion complexes: characterization, protection and emulsification properties. *Food Chem.* **175**: 529–35.
- 152 Virtamo J, Taylor PR, Kontto J, Männistö S, Utriainen M, Weinstein SJ, Huttunen J, Albanes D (2014). Effects of  $\alpha$ -tocopherol and  $\beta$ -carotene supplementation on cancer incidence and mortality: 18-year postintervention follow-up of the Alpha-tocopherol, Beta-carotene Cancer Prevention Study. *Int J Cancer.* **135**(1): 178–85.
- 153 Voigt A, Hartmann P, Zintl F (2000). Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid. *Cell Adhes Commun.* **7**(5): 423–40.
- 154 Wald G (1960). The visual function of the vitamins A. *Vitam Horm.* **18**: 417–30.
- 155 Walder S, *et al.* (1997). All-trans retinoic acid and interferon- $\alpha$ -2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. *Cancer.* **79**(8): 1574–1580.
- 156 Wang L, Li B, Pan MX, Mo XF, Chen YM, Zhang CX (2014). Specific carotenoid intake is inversely associated with the risk of breast cancer among Chinese women. *Br J Nutr.* **111**(9): 1686–95. Epub 2014 Feb 6.
- 157 Watters JL, Gail MH, Weinstein SJ, Virtamo J, Albanes D (2009). Associations between  $\alpha$ -tocopherol,  $\beta$ -carotene, and retinol and prostate cancer survival *Cancer Res.* **69**(9): 3833–41. Apr 21.
- 158 Wu XX, Kakehi Y, Jin XH (2009). Induction of apoptosis in human renal cell carcinoma cells by vitamin E succinate in caspase-independent manner. *Urology.* **73**(1): 193–9.
- 159 Wu K, Li Y, Zhao Y, Shan YJ, Xia W, Yu WP, Zhao L (2002). Roles of Fas signaling pathway in vitamin E succinate-induced apoptosis in human gastric cancer SGC-7901 cells. *World J Gastroenterol.* **8**(6): 982–6.
- 160 Yamamoto Y, Zolfaghari R, Ross AC (2000). Regulation of CYP26 (cytochrome P450RAI) mRNA expression and retinoic acid metabolism by retinoids and dietary vitamin A in liver of mice and rats. *FASEB J.* **14**(13): 2119–27.
- 161 Yang QJ, Zhou LY, Mu YQ, Zhou QX, Luo JY, Cheng L, Deng ZL, He TC, Haydon RC, He BC (2012). All-trans retinoic acid inhibits tumor growth of human osteosarcoma by activating Smad signaling-induced osteogenic differentiation. *Int J Oncol.* **41**(1): 153–60. Epub 2012 Apr 3.
- 162 Yin Y, Ni J, Chen M (2009). RRR- $\alpha$ -vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. *Clin Cancer Res.* **15**(1): 190–200.
- 163 Yu A, Somasundar P, Balasubramanian A, Rose AT, Vona-Davis L, McFadden DW (2002). Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor. *J Surg Res.* **105**(1): 65–8.
- 164 Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, Kline K (1999). Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. *Nutr Cancer.* **33**(1): 26–32.
- 165 Yu W, Sanders BG, Kline K (1997). RRR- $\alpha$ -tocopherol succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. *Nutr Cancer.* **27**(1): 92–101.
- 166 Zhang X, Dai B, Zhang B, Wang Z (2012). Vitamin A and risk of cervical cancer: a meta-analysis. *Gynecol Oncol.* **124**(2): 366–73. Epub 2011 Oct 15. Review.
- 167 Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S (2002). Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. *Proc Natl Acad Sci U S A.* **99**(11): 7408–13.
- 168 Zhong M, Kawaguchi R, Ter-Stepanian M, Kassai M, Sun H (2013). Vitamin A transport and the transmembrane pore in the cell-surface receptor for plasma retinol binding protein. *PLoS One.* **8**(11): e73838.